Baycox Iron Injection is indicated for the concurrent prevention of clinical signs of coccidiosis (such as diarrhoea) in neonatal piglets on farms with a confirmed history of coccidiosis caused by Cystoisospora suis, and the prevention of iron deficiency anaemia.
Professor Nicole Kemper, Director of the Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour at the University of Veterinary Medicine Hannover in Germany said: "Piglets go through intense handling in their first days of life. While this is done to give them a better start to life and protect them from disease, it can also cause a lot of stress. Measures to reduce the need for piglet handling can make an important contribution to enhancing piglet well-being in the farrowing pen."
Octavio Orlovsky Eckhardt, Head of Species Marketing Swine at Animal Health, Bayer said: "A combination therapy that can effectively address these concerns with reduced handling can make a real difference for pig health and well-being.
"At the same time, farmers and workers can benefit from the reduced labour. For example, on a 1,000 sow farm, the reduced complexity is estimated to save up to one full work day every month."
For more information on Baycox Iron Injection, contact your local Bayer Animal Health representative.
The company says Cevaprost can help improve breeding success in reproduction protocols in cattle and has the following indications:
Ceva says these indications are equivalent to those of the leading racemic and single isomer cloprostenols available in the UK.
Cevaprost is available in a 20ml colourless glass vial and in a multi-pack of 10 x 20ml vials. It can be administered in single or repeated 2ml doses (equivalent to 0.5mg of cloprostenol) by intramuscular injection. It has a withdrawal period of one day for meat and no withdrawal period for milk.
Peter Keyte, ruminant business unit manager at Ceva Animal Health, said: “We are delighted to add Cevaprost to our extensive range of reprodAction products to provide vet and farmers with comprehensive cattle reproduction solutions and improve breeding success in reproduction protocols.”
For further information, contact your local Ceva territory manager or email cevauk@ceva.com.
Intervet/Schering-Plough Animal Health has launched a new oxytetracycline spray which the company says offers more accurate antibiotic delivery whether the can is used in an upright or inverted position.
Alasdair King MRCVS, Intervet/Schering-Plough Animal Health veterinary manager, says new Engemycin Spray has been developed specifically to address problems reported with traditional aerosol cans:
"Antibiotic sprays are used widely, yet they can become a practical nuisance to both vets and farmers simply because many cans do not perform satisfactorily. All too frequently the nozzle leaks or detaches, the spray pattern is irregular - particularly if the can is held upside down as it so often needs to be - or the valve clogs before the can is empty. This can be a source of great frustration to users, but new Engemycin Spray overcomes all these problems."
Intervet/Schering Plough says Engemycin Spray combines a unique, quick-drying formulation with an innovative, non-clogging spray valve. The quick-drying formulation minimises wastage from the sprayed area, while the new valve - which works as well when the can is upside down - cuts spraying time and ensures more reliable and constant delivery of antibiotic. The valve is unique and designed to enable the can to fully empty.
Engemycin Spray is licensed for the treatment of foot and wound infections in cattle, sheep or pigs following surgery or physical injury. The new product is available now from wholesalers.
Defra has announced the detection of Bluetongue in 18 imported cattle on premises near Bishop Auckland, County Durham. The animals originated from within the BTV8 Restricted Zone in Germany and were detected as a result of post-import testing carried out by Defra on all Bluetongue susceptible animals arriving from Continental Europe.
This is the fourth incidence of infected animals being imported to the UK. Alongside the premises in East Sussex, Hertfordshire and Devon identified in August, the imported animals will remain under restrictions.
As of 1 September the whole of England and Wales is now in a Protection Zone and approximately 30 million doses of vaccine have so far been made available to farmers throughout England and Wales to protect their stock. However, it may take up to six to eight weeks from now for livestock keepers in the North of England and Wales to have had sufficient opportunity to vaccinate their livestock and to gain immunity (at least three weeks in sheep, and six weeks in cattle).
To allow livestock keepers in those areas sufficient opportunity to protect their animals, and while further veterinary investigations are carried out, these particular infected animals will remain under restriction until late October. Any further positive import cases detected may also be restricted for a period of time depending on veterinary risk assessment, while vaccination continues.
Deputy Chief Veterinary Officer, Alick Simmons said: "This incident shows how important it is for farmers to consider potential disease risks when buying stock, regardless of source. Buyers need to consider how best to protect their own businesses and those of their neighbours and make sure they are clear about the stock they are intending to buy.
"I also want to remind farmers about the importance of vaccination. It is the only effective tool to protect susceptible animals from Bluetongue. Recent evidence indicates a drop or delay in vaccine take-up in counties recently brought into the Protection Zone. Sales data for some of those counties suggest that the number of animals vaccinated in these areas could be as low as one in three, and in Northumberland and Cumbria, the most recent counties brought into the Protection Zone, as low as one in five.
"The threat from Bluetongue is present and real, as shown by the most recent import cases. Vaccination as a preventive measure is therefore more important than ever, so the message to the industry remains clear: don't hesitate, vaccinate".
The review coincided with a move last month from RUMA, the agricultural and food industry alliance which promotes responsible use of medicines in farm animals, to align with the EMA position.
The announcement means that under PVS guidelines, fluoroquinolones, 3rd and 4th generation cephalosporins and colistin will retain Class 3 status. This means they are only used when no other options are available and when supported by laboratory sensitivity testing – or exceptionally when all other options have failed.
Class 1 antibiotics form the standard prescribing list within responsible use guidelines and Class 2 are used only when sensitivity tests or clinical experience proves standard antibiotics are not effective. In all treatment decisions the health and welfare of the pigs must always take priority.
Betalactams with betalactamase inhibitors (clavulanic acid) were previously in the highest priority Class 3 but in light of the list defined by the EMA, which has been adopted by the Veterinary Medicines Directorate as well as RUMA, the PVS has reassessed the risk and moved them to Class 2 to align them with plain betalactams. This means they are still subject to voluntary restrictions, but their use would not necessarily be only as a last resort.
PVS president Mark White said that despite the ongoing review process and the potential to reclassify certain products, the Society’s underlying principles remain unchanged: "The total amount of all antibiotics used on pig farms to treat and prevent disease should be minimised, and the types of antibiotics used in pigs should be considered in light of the implications for antibiotic resistance challenges in both pigs and man.
"This policy is proving successful with AHDB Pork’s electronic pig medicine book (e-MB) recently showing that use of colistin appears to have fallen by over 70% in 2016 following its move to a Class 3 antibiotic in late 2015.
"We must also continue to be alert to the possibility of cross resistance, even in older antibiotics that have little or no use in humans. Risk must be acknowledged where it exists and overall reductions are still imperative."
RUMA has welcomed the review and alignment from the PVS. Secretary General John FitzGerald said: "Farmers and vets need boundaries within which to operate and clear objectives to meet, and we would urge all supply chains, from farmer to retailer, to align with the sector position on best practice use of antibiotics, as defined by each sector’s professional veterinary organisation."
Improve International has announced that it is to hold the first conference aimed specifically at Official Veterinarians.
Taking place from 22-23 October 2015, Improve says the conference aims to provide a forum to update OVs on the latest developments and thinking on all aspects of OV work and to provide an opportunity to network and share experiences and ideas.
Organised in association with the Animal & Plant Health Agency (APHA), the Official Veterinarian Conference programme includes a two-day stream of large animal lectures and round-table discussions on topics including Bovine TB, Brucellosis, Anthrax, Sheep Scab and other important diseases.
A lecture stream for small animal practitioners will provide updates on export regulations and small animal exotic diseases, with dedicated lectures for equine practitioners also running on Friday 23 October.
Speakers at the event include Peter Jinman, Chair of the RCVS Certification Sub-Committee (pictured right); Dr Tim Brazil, Directorate of Equine Medicine on the Move and Andy Paterson, Veterinary Head of Intervention Epidemiology. An exhibition of the latest products and services for OVs will run alongside the conference which takes place at the Alexandra House Hotel and Conference Centre, near Swindon, where Improve International is based.
David Babington MRCVS, Managing Director of Improve, said: "The world of the OV is a fast-changing one so this unique event provides an opportunity for OVs to come together in a relaxed atmosphere to hear industry experts deliver up-to-date and practical lectures which will have a positive impact on their work as an OV.
"The programme and content has been developed by our Scientific Committee in collaboration with APHA which is supporting us and we believe it will offer highly relevant content for all OVs."
Are you planning to come to this event? If so, indicate it here, so other VetSurgeon members can see you'll be there!
To book, visit www.officialvet.com
With just a few days to go before the first anniversary of bluetongue being detected in England, the JAB campaign group is urging farmers to vaccinate their livestock to stop the disease from taking hold in this country as it has in Europe.
So far this year France has reported 4,543 cases of bluetongue, including cases in Calais, and the Netherlands has just confirmed its first case of the disease in 2008. The affected small holding reported a sick cow found with serotype eight which had not been vaccinated against infection.
With the threat of bluetongue re-emergence in the UK growing by the day, JAB leaders have issued a reminder to farmers to contact their vets as soon as their region is in the protection zone and vaccine is available.
In a statement JAB said: "The amount of cases being reported across Europe shows the disease is on the move. This most recent case in Holland demonstrates that not vaccinating livestock leaves farmers vulnerable to outbreaks now the midge season has started.
"The industry has rallied behind the JAB campaign and has done tremendously well in terms of vaccination. Nearly 19 million doses have already been made available to English farmers, and with another nine million doses planned to be released in the coming weeks we need those areas that are new to the protection zone to vaccinate as soon as they are able. We must remember bluetongue could already be circulating in areas where outbreaks occurred last year so the risks to everyone are very real.
"The explosion in the number of cases on the continent also acts as a timely reminder to those farmers in the current protection zone who have not vaccinated and the dangers this presents to their unprotected livestock
"We are entering the peak period for midge activity so vaccination is the only way to prepare and protect us from any potential outbreaks that may emerge in the coming weeks."
BVA President Gudrun Ravetz said: "Veterinary View not only highlights some of the veterinary profession's fantastic work, but complements our joint project with RCVS, Vet Futures, in exploring how the profession can best shape its own future. We hope it will stimulate debate among vets, and the wider community in which we work, about both the big challenges and opportunities that the veterinary profession is facing."
The series includes a number of videos which showcase more recent industry developments:
Stem Cell therapy for the treatment of canine osteoarthritis (VetCell Therapeutics)
Pharmtrax, a mobile device for vets to record work and dispensing on the farm (Henry Schein Animal Health)
Hormone implants as an alternative to castration (Virbac Animal Health)
Practice management support from Zoetis
Preventing an epidemic of equine flu (Merial Animal Health)
Intervet/Schering-Plough has announced that Estrumate®, in both the 10ml and 20ml vial size is back in stock and available to order from your veterinary wholesaler.
The stock out situation had arisen as a result of increased demand during the early part of the year but the company is confident that there will be sufficient stock to supply the increased level of demand in the foreseeable future. Intervet/Schering-Plough would like to thank their clients for the patience and understanding.
Further information is available from Intervet/Schering-Plough Account Managers or the Veterinary Support Group (VSG) on 01908 685685.
The Veterinary Record has published what the British Homeopathy Association is calling the first ever systematic review of randomised controlled trials (RCTs) in veterinary homeopathy.
The review was conducted by Dr Robert Mathie, research development adviser to the association, and Dr Jürgen Clausen from the Carstens Foundation, Germany.
They found 18 placebo-controlled RCTs of veterinary homeopathy, published in the peer-reviewed literature, that were eligible for detailed assessment. Of these, only two were judged to provide reliable evidence. The remainder were unclear or had a high risk of bias.
The two studies which were judged reliable were:
HEKTOEN, L., LARSEN, S., ØDEGAARD, S. A. & LOKEN, T. (2004) Comparison of homeopathy, placebo and antibiotic treatment of clinical mastitis in dairy cows - methodological issues and results from a randomized-clinical trial. Journal of Veterinary Medicine. A, Physiology, pathology, clinical medicine 51, 439-446. In this study, homeopathy was shown to be ineffective.
Dr Mathie said: "Up to now, debates about the efficacy or effectiveness of veterinary homeopathy have been polarised by the absence of any systematic review of the subject. Our work clarifies the nature of the current RCT evidence."
Mr Mark Elliott, immediate past president of the British Association of Homeopathic Veterinary Surgeons, said: "This important study affirms that reliable evidence does exist and that more research should be done, particularly in light of current concerns about antibiotic resistance in production animals."
It seems a remarkable admission, that the entire veterinary homeopathy edifice rests upon one study in piglets. However, if that study did prove the efficacy of homeopathy, it would of course be an order of magnitude more remarkable than today's admission.
So, no pressure then, Camerlink et al!
Defra / APHA will provide an update on the current situation, followed by a presentation about BTV by Peter Mertens, Professor of Virology, University of Nottingham, and Christopher Sanders, Research Fellow in Veterinary Entomology from the Pirbright Institute.
If can't attend, you can register to be sent a recording afterwards.
This is the first of a series of bluetooth update webinars which will be held fortnightly on Wednesdays at 6pm.
https://ahdb.org.uk/events/bluetongue-virus-technical-webinar
MSD Animal Health has launched a new Chronogest CR pack for practices starting a dialogue with sheep producer clients about planned breeding for 2013 lamb sales, and is offering a free applicator with every four packs purchased.
The Chronogest CR intra-vaginal sponges, impregnated with 20mg of cronolone (flugestone acetate) synthetic hormone, are now available in foil wrapped packs of 25. The packs protect the sponges from light and moisture.
MSD is reminding practitioners that sponging programmes must be planned at least six weeks in advance of mating, with PMSG-Intervet injections essential at sponge removal.
The new packs of 25 will be available when existing 25, 50 and 100 pack sizes sell out.
Further information on planned breeding - including newsletter copy and sheep producer advisory materials - is available from the MSD Animal Health veterinary support group (VSG) on 01908 685685 or via emailing vet-support.uk@merck.com
Intervet/Schering-Plough Animal Health has launched its complimentary blood testing service that allows practitioners to investigate one of the main infectious causes of early embryo loss in sheep flocks.
The annual subsidised Barren EweCheck diagnostic scheme is available from 1st December 2009 until 31st March 2010 for breeding ewe flocks. The service establishes whether Toxoplasma gondii is potentially implicated in any empty or aborting ewes.
ISPAH says that data from the 2009 scheme showed that 69% of flocks had been exposed to the toxoplasma parasite at some point before blood sampling. As a result, practitioners were able to give clients receiving a positive diagnosis timely advice on disease control and the benefits of a Toxovax vaccination regime.
Further information and the 2010 Barren EweCheck pads are available directly from the company's Veterinary Support Group by calling 01908 685685.
Dr Berwyn Clarke, CEO of PBD Biotech, which developed the bacteriophage-based detection method, says this is significant step forward: "In situations where a farm has had an ongoing chronic bovine TB problem, APHA’s protocol offers a promising new approach to controlling the infection.
"Actiphage is now included within a series of measures that farmers can use in conjunction with their vet and with specific APHA approval as a means to improving their disease management strategy.
"For many farms that have been struggling for years it provides the first step to becoming TB free. This move by the APHA is a really positive step towards tackling this devastating disease."
Much of this new strategy, as part of a private TB eradication plan, has been driven by the success of Devon-based vet Dick Sibley, who incorporated Actiphage into a disease management strategy last Autumn to help clear a dairy herd that had been stricken with TB since 2012.
Dick said: "The approach of directly measuring the presence of live bacteria in the blood in just six hours is a totally different but complementary measurement to other technologies and has enabled enhanced testing, early detection and containment of the infected animals.
"We don’t have all of the answers yet, but it’s about predicting, preventing and managing what we can – and Actiphage has contributed greatly to the outcome we’ve been after for so long."
The Exceptional private use of non-validated tests for TB on cattle in England protocol enables any private veterinary surgeon to request APHA permission for exceptional use of Actiphage and the other non-validated tests, subject to certain criteria that include herd supplementary interferon-γ (IFN- γ) testing, discussions with the APHA Case Vet and the farmer’s written consent.
Berwyn added: "Actiphage is unique in directly detecting live mycobacteria in blood or milk, and it can also distinguish between a vaccinated and an infected animal - paving the way for new types of disease control when vaccines become available in the future.
"We are working with international governments, and the test is being trialled on bovine, ovine as well as exotic species, but we appreciate it is new to the UK market so we’re keen to answer any queries vets or farmers may have."
The new test will be profiled in the Innovation Hub at the Royal Norfolk Agricultural Show next month (27 & 28 June).
PBD Biotech says Actiphage will require further testing before it is officially approved for standard veterinary use in the UK, however under the APHA protocol it is now permitted for private use where herds have experienced persistent breakdowns and this will contribute to the evidence-base required for official validation by the OIE and acceptance by APHA.
Within this protocol, APHA has outlined a number of other non-validated tests that may be proposed for exceptional use in cattle herds with chronic breakdowns, including: the Actiphage assay, developed by PBD Biotech and Nottingham University; the Enferplex TB serological test, produced by Enfer Laboratories Ireland and approved in GB for use in camelids; and the Polymerase Chain Reaction (PCR) testing of faecal samples. APHA says this is not an exhaustive list and that the protocol covers any current or future non-validated tests for bovine TB.
The comparative intradermal tuberculin skin test and the IFN- γ blood test remain the only ante mortem tests currently approved for the statutory cattle TB testing programme in Great Britain.
The full Exceptional private use of non-validated tests for TB on cattle in England is available on the APHA Vet Gateway: apha.defra.gov.uk/vet-gateway/non-valid-tb-testing
Hysolv Animal Health has announced the launch of Salmovac 440, a new live salmonella vaccine for poultry which the company claims gives earlier, stronger and longer-lasting immunity than other salmonella vaccines.
The vaccine is given orally through the water supply in a three-dose regime that protects against Salmonella Enteritidis (SE) and Salmonella Typhimurium (ST). It also protects against other SE strains and the newly-emerging monophasic Salmonella Typhimurium strains.
Hysolv says the advantage for farmers is that the vaccine strain is robust and can survive in more hostile conditions. It therefore remains effective where the water delivery system is less than ideal.
The first dose is administered from Day 1 followed by a second dose at six weeks and a third as early as 11 weeks. Salmovac 440 protects chicks after six days and remains effective for up to 63 weeks after the third vaccination, providing an extra four weeks of protection.
Hysolv says another important benefit to egg producers is that the earlier final vaccination at 11 weeks means that the birds can be moved into the laying house as early as 16 weeks old if required — a significant management advantage on some farms.
During the development of the vaccine it was found that the third live vaccination tended to ‘shut down’ any prolonged shedding of the vaccine strain. This, coupled with the earlier vaccination at 11 weeks, helps solve the issue of the vaccine strain being found at transfer to the layer house. Dr Daniel Windhorst, salmonella vaccine specialist with IDT Biologika, said: "If any should be found, the new PCR (Polymerase Chain Reaction) test shrinks the testing time to just two to three hours."
Daniel added: "Although the UK has one of the lowest percentages of salmonella in its flocks, almost one-third of cases were of S Typhimurium. In most continental countries the percentage is much higher, so the extra cover provided by this vaccine is important."
Salmovac 440 has been approved for use by the British Egg Industry Council, which administers the Lion Code.
The BVA is calling for urgent reassurance from the government concerning farm animal welfare.
The association says the government decision to revoke farm animal welfare codes risks undermining public confidence in animal welfare standards.
When Defra consulted in 2013 on proposals to move away from statutory codes to non-statutory, industry-led guidance BVA broadly supported more flexibility to allow for guidance to be updated more regularly and in light of new welfare science, but raised a number of questions regarding enforcement and, critically, around the definition of 'industry'.
BVA emphasised that veterinary surgeons, farmers, animal welfare scientists with species-specific knowledge, industry bodies and other groups must all be involved and consulted.
BVA also warned Defra of implications in relation to the message conveyed to stakeholders by such a change and the value attached to the welfare codes by the government.
BVA President Sean Wensley, said: "It is essential that any changes to the welfare codes do not undermine public confidence in the high animal welfare standards set for English farms. Although BVA broadly supported the idea of moving to a more flexible system that could take account of new animal welfare science, we maintained that a range of expertise must be used to draw up new guidance.
"We are pleased that there will be no changes to the legislation that underpins animal welfare but it is unclear where the checks and balances now lie. It is vital that Defra puts measures in place urgently to provide that reassurance.
"The Secondary Legislation Scrutiny Committee has suggested that it would be possible for the fundamental principles to be laid down in statutory codes which are subject to parliamentary scrutiny with operational details being set out in guidance. This idea may be worth further exploration to allow both the flexibility required to reflect new animal welfare science and the public confidence that the statutory welfare codes currently provide."
Novartis Animal Health has launched a 0.5L pack of the anthelmintic Zolvix to make the product more readily available for quarantine dosing, and for the smaller sheep farmer.
Novartis says that because Zolvix is a broad spectrum anthelmintic that has the ability to kill all common sheep gastro-intestinal nematodes, including those resistant to existing treatments, it has a key role to play in quarantine treatment to keep parasite infection down to a minimum.
Simon Harris, Endoparasite Brand Manager at Novartis Animal Health, said: "As the first of the new generation of the Orange or 4-AD anthelmintic group, Zolvix has demonstrated effectiveness in killing worms, even those resistant to other products.
"Sheep farmers are being encouraged to use Zolvix as a quarantine treatment that can significantly reduce worm burdens on farm. I would stress that it is essential guidelines are followed in order to preserve Zolvix's ability to combat nematodes that have acquired resistance to other classes of wormers.
"This new pack size is aimed at farmers who are introducing new stock to their flocks, but will also be convenient for the smaller sheep farmer and smallholders who don't require such a large quantity of product."
Novartis says that because Zolvix is a short-acting anthelmintic, it does not encourage resistance to develop through a long duration of action. It has a high margin of safety so can be used to treat sheep and lambs including pregnant or lactating ewes and breeding rams. Its short meat withhold period of just seven days allows flexibility when marketing lambs.
The new facilities use teaching aids and models to allow students to refine their practical skills and build confidence before being let loose on real patients.
As part of the official opening, Princess Anne toured the School of Veterinary Medicine, where she met with staff and students and saw a demonstration of a new equine gut model that offers an alternative to using live animals for research into the gut microbiota of horses and how they are affected by diet, disease and medication.
Professor Chris Proudman, Head of the School of Veterinary Medicine, said: "We are honoured to welcome The Princess Royal to the Vet School today, and very grateful that Her Royal Highness has officially opened the Large Animal Clinical Skills Facilities. Preparing students for life as a vet is our number one priority; the hands-on experience they will get through the use of this facility is invaluable and enables them to give the best possible care to all animals.
"We are also very grateful to the Longhurst family, without whom these teaching resources would not have been possible – their generosity is helping us to teach the vets of the future."
5638 events were reported spontaneously, mainly by the marketing authorisation holder (61%), with the remainder largely reported by veterinary surgeons.
Of these, 5512 were reports of adverse reactions in animals: 829 concerning suspected lack of efficacy, 4638 concerning safety. The majority of reports concerned dogs (2927), cats (1426) and cattle (386).
In dogs, medicines for the control of epilepsy were most often suspected of not having performed as expected (80 reports) whilst vaccines were most commonly reported as having failed to work (71). However, the VMD points out that in many cases, vaccination failure was attributable to other causes (such as incomplete vaccination schedule).
In cats, flea spot-on products were most likely to be reported as not having worked (21). However, there are many reasons why owners may continue to see live fleas on their animal which are unrelated to product efficacy (such as reinfestation from the environment).
Notably, the majority of efficacy reports in horses (12/19) related to euthanasia products, which the report says should serve as a reminder that alternative means of euthanasia should always be available in case the chosen method does not proceed as planned.
Of the safety reports, 59.6% involved dogs, 31% cats, 4.9% horses and 3.9% rabbits. The majority concerned vaccines (1360 reports, most commonly general signs or symptoms, such as lethargy or pyrexia), parasiticides (472 reports, most commonly lethargy, emesis, inflammation/pruritus, depending on method of administration) and inflammation control (412 cases, most commonly emesis, renal insufficiency and diarrhoea, depending on the drug type).
There were 124 reports of adverse events in humans. Of those involving veterinary professionals (about a quarter):
The VMD says that reports of needle stick injuries involving vaccines with a mineral oil adjuvant are of particular concern, because they often fail to show that the injured party has received prompt and correct treatment, either because they are themselves unaware of the necessity for swift intervention, or because they do not take the product package information leaflet with them when seeking medical treatment.
Similarly, the VMD says that incidents involving injectable tilmicosin seem to be often dismissed as just a scratch, and that if you use these products, you should make sure you are fully aware of the warnings contained in the product leaflets.
To read the full report, visit: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/608968/PhV_Annual_Review_2015_v7.pdf
Virbac says that this means that irrespective of previous vaccination history, only a single injection of the vaccine given 12-3 weeks prior to calving is required to boost cow serum and therefore colostrum antibody levels against rotavirus, coronavirus and E. coli (K99) - the major and most common viral and bacterial causes of diarrhoea in dairy and beef calves.
Dr. Rosie Reyneke, Farm Animal Technical Product Manager at Virbac said: "Bovigen Scour is the most recent single shot scour vaccine on the market, and now with the ease of use afforded by the new 1-shot protocol, will allow our customers to engage more deeply with farmers to develop the use of vaccination as a preventative means to improve the welfare of the UK’s dairy and beef calves."
Virbac says it has worked closely with the UK veterinary profession to ensure that the product performs well under UK conditions. Rosie added: "2018 marks 50 years of Virbac working in partnership with the veterinary profession around the world, and in following our traditions, we have engaged a number of prominent dairy and beef veterinary practices to test this, from John O’Groats in the north to Land’s End in the south. We wanted to be absolutely sure our vaccine meets the highest possible expectations of beef and dairy farmers across the UK”.
For the study1, 158 cows presented with active DD (M1, M2 or M4.1 stage) and were randomly allocated to either the control or the treatment group.
All cows were treated with a topical application of oxytetracycline spray.
The treatment group also received an intramuscular injection of Ketofen 10% solution for injection (ketoprofen 3mg/kg).
Cows were mobility scored just before they were treated and then again one week later.
The results indicated that animals in the control group were 2.57 times more likely to be lame at the second evaluation compared to those that received Ketofen, however cows that were lame in the control group prior to treatment and did not receive Ketofen were over 20 times more likely to remain lame a week post-treatment compared to cows that did receive Ketofen.
The same study all showed a milk yield benefit overall; treated cows produced 2.98 kg more milk than control cows (T = 45.35 C = 42.37, p<0.01).
When only lame fresh cows were considered, there was a 10.49kg increase in milk yield (T = 58.38 C = 47.89 p<0.05).
Nick Bell MA, VetMB, PhD, PGCert Vet Ed, FHEA, DipECAWBM(AWSEL), MRCVS, veterinary surgeon and director of Herd Health Consultancy, said: “We’ve widely recognised the importance of NSAIDs for treating claw lesions, which are primarily inflammatory conditions, but this study is the first real insight into how important NSAIDs are for any lesion, including digital dermatitis, particularly if the cow is showing signs of lameness.
"This research provides a clear welfare justification for giving NSAIDs to dairy cows with active digital dermatitis lesions, with significant milk yield benefits.”
Katherine Timms BVetMed(Hons) MRCVS, ruminant veterinary advisor at Ceva Animal Health said: “While it is recognised that some stages of digital dermatitis are painful, there has been little research to determine the value of including analgesia in the treatment of the condition.
“This study suggests that the use of Ketofen in the treatment of pain and lameness associated with active digital dermatitis lesions may be beneficial for animal welfare as it is associated with an improvement in mobility scores.”
Reference
Intervet/Schering-Plough Animal Health has produced a new Orf Vaccination Starter Pack to help vets better inform their sheep farmer clients about the disease.
The new campaign Vaccination Starter Pack includes a practical guide to Orf and its control in UK sheep flocks, a DVD profiling vet and farmer experiences of managing the disease, an 'Orf questions answered' handout and a best practice vaccination protocol. Additional practice support materials highlighting the problems caused by Orf and its control with Scabivax Forte are also available.
The Starter Pack and full range of promotional materials are available from local Intervet/Schering-Plough Account Managers or by contacting the Veterinary Support Group on 01908 685685.